Medicine:Leukocyte apheresis
From HandWiki
Short description: Medical device therapy
| Leukocyte apheresis | |
|---|---|
| Specialty | Gastrointestinal |
Leukocyte apheresis is a medical device therapy (selective granulocyte/monocyte adsorptive {GMA} apheresis; GMDN[1] code: 47306) for the treatment of inflammation of the colon. It works by removing from the blood a group of white blood cells called activated leukocytes[2] that play a key role in the inflammatory stages of ulcerative colitis (UC).[3] Selectively reducing these cells in the blood helps to reduce inflammation in the colon.[4] Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above.[5]
References
- ↑ "Global Medical Device Network". https://www.gmdnagency.com.
- ↑ Hanai H. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology 163 (1): 50–58. doi:10.1111/j.1365-2249.2010.04279.x. PMID 21078086.
- ↑ Nikolaus S., Schreiber S. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut 42 (4): 470–476. doi:10.1136/gut.42.4.470. PMID 9616306.
- ↑ Muratov V. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis.". Journal of Gastroenterology 43 (4): 277–282. doi:10.1007/s00535-007-2156-3. PMID 18458843.
- ↑ Dignass A. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". The European Crohn's and Colitis Organisation (ECCO). https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/abstracts-2015/item/p511-efficacy-and-safety-of-granulocytemonocyte-adsorptive-apheresis-in-steroid-dependent-active-ulcerative-colitis-with-insufficient-response-or-intolerance-to-immunosuppressants-andor-biological-therapies-the-art-trial-results-at-24-and-48-weeks.html?highlight=YToxOntpOjA7czo5OiJhZGFjb2x1bW4iO30.
 |  |
